ReviewTherapeutic advances in psychopharmacology2020
Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products.
Review in Therapeutic advances in psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07638189 (Pilot Study Using Topical Cannabidiol), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Study Using Topical Cannabidiol (CBD) to Manage Osteoarthritic Knee Pain
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Cannabidiol and Cannabidiol Metabolites: Pharmacokinetics, Interaction with Food, and Influence on Liver Function.Nutrients · 2022Trial
- Cannabis use within the United States: Prevalence of cannabis use by state legal status and perceptions of benefit and harm.Drug and alcohol dependence reports · 2026Article
- Sex differences in the disposition of cannabidiol and its metabolites in mice.Journal of cannabis research · 2026Article
- Sex-specific association between low oral doses of cannabidiol (CBD) and plasma concentration of anandamide (AEA), N-palmitoylethanolamine (PEA) and N-oleoylethanolamine (OEA) in healthy occasional cannabis users.Journal of cannabis research · 2026Article
- Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis.Frontiers in psychiatry · 2026Article
- Navigating Global Regulatory Divergence in Over-the-counter Drugs: Addressing Emerging Risks and Harmonization Challenges.Current drug research reviews · 2026Review
- Medicinal use of non-prescribed cannabis: a cross-sectional survey on patterns of use, motives for use, and treatment access in the Netherlands.Journal of cannabis research · 2025Article
- Medicinal cannabis: is current use clinically justified?Internal medicine journal · 2025Review
- Cannabidiol in Foods and Food Supplements: Evaluation of Health Risks and Health Claims.Nutrients · 2025Review
- The Development of Cannabinoids as Therapeutic Agents in the United States.Pharmacological reviews · 2024Review
- The attitudes, knowledge and confidence of healthcare professionals about cannabis-based products.Journal of cannabis research · 2024Article
- Comparing Cannabis Use for Pain to Use for Other Reasons in Primary Care Patients.Journal of the American Board of Family Medicine : JABFM · 2024Article
- The potential for medicinal cannabis to help manage challenging behaviour in people with intellectual disability: A perspective review.Journal of psychopharmacology (Oxford, England) · 2023Article
- Dysmenorrhoea: Can Medicinal Cannabis Bring New Hope for a Collective Group of Women Suffering in Pain, Globally?International journal of molecular sciences · 2022Review
- Individual and combined effects of cannabidiol and ΔJournal of psychopharmacology (Oxford, England) · 2022Article
- Over-the-counter drug use in suicidal/self-harm behavior: Scoping review.Health science reports · 2022Article
- Patterns and correlates of cannabidiol product and marijuana co-use in a sample of U.S. young adults.Addictive behaviors · 2022Article
- Acceptability of cannabidiol in patients with psychosis.Therapeutic advances in psychopharmacology · 2022Article
- Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19.International journal of molecular sciences · 2021Review
- Impact of Cannabis Use on Least Pain Scores Among African American and White Patients with Cancer Pain: A Moderation Analysis.Journal of pain research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Over the past 5 years, public interest in the potential health benefits of cannabidiol (CBD) has increased exponentially, and a wide range of over-the-counter (OTC) preparations of CBD are now available. A substantial proportion of the population appears to have used these products, yet the extent to which they are effective or safe is unclear. We reviewed the evidence for whether CBD has significant pharmacological and symptomatic effects at the doses typically found in OTC preparations. We found that most of the evidence for beneficial effects is derived from studies of pure, pharmaceutical grade CBD at relatively high doses. Relatively few studies have examined the effect of OTC CBD preparations, or of CBD at low doses. Thus, at present, there is little evidence that OTC CBD products have health benefits, and their safety has not been investigated. Controlled trials of OTC and low-dose CBD preparations are needed to resolve these issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.